

Recommendations of the European Working Group for Adult ALL



UNI-MED Verlag AG
Bremen - London - Boston

Contents

1.	Approach to the Patient with a Suspect of ALL	24
1.1.	Clinical diagnosis, required lab and other tests	24
1.2.	Morphology and cytochemistry	24
1.3.	Immunophenotyping	25
1.4.	Cytogenetics	26
1.5.	Molecular genetics	27
1.6.	Gene expression profiling	28
1.7.	Minimal residual disease	29
1.8.	Organization of central diagnosis and cell banking	29
1.9.	Most important differential diagnoses	29
2.	Appropriate Setting for Management of ALL	34
2.1.	Medical care	34
2.1.1.	Appropriate facilities for acute leukemia patients	34
2.1.2.	Management during induction therapy and during high dose therapy with or without SCT	34
2.1.3.	Evaluation procedures of treatment	36
2.1.3.1.	Induction therapy and high dose therapy with or without SCT	36
2.2.	Psychological approach (assistance) of the patient and the family	36
2.3.	Physical sustenance	36
2.4.	What would a patient with ALL like to know	37
3.	Prognostic Factors and Risk Adapted Therapy	40
3.1.	Symptoms and clinical markers	40
3.2.	Immunologic subgroups	40
3.3.	Cytogenetics	41
3.4.	Molecular genetics	41
3.5.	Gene expression profiles	43
3.6.	Pharmacogenetics	43
3.7.	Others	44
3.8.	Models for risk stratification	45
4.	Supportive Care	54
4.1.	General measures	54
4.2.	Anti-emetics	54
4.3.	Anti-infection prophylaxis	56
4.4.	Transfusion policy	58
4.5.	Growth factors	59
4.6.	Menstruation prophylaxis and preservation of fertility	60
5.	Treatment of ALL	66
5.1.	Induction therapy	66
5.1.1.	Risk stratification and definition of subgroups	66
5.1.2.	Standard approach	66
5.1.3.	Targeted therapy and future options	69

5.2.	Consolidation therapy	73
5.2.1.	Standard approach	73
5.2.2.	Risk- and MRD-oriented approach	74
5.2.3.	Integration with allogeneic SCT and autologous SCT	75
5.2.4.	Pediatric-type regimens	76
5.3.	CNS prophylaxis	79
5.3.1.	CNS involvement at diagnosis	80
5.3.2.	Risk factors for CNS relapse	80
5.3.3.	Approaches for treatment and prophylaxis of CNS relapse	80
5.3.3.1.	Intrathecal therapy	80
5.3.3.2.	Combination approaches	81
5.3.3.3.	Cranial irradiation	81
5.3.4.	Practical aspects.	82
5.3.5.	Potential neurotoxicities related to CNS-directed treatment or prophylaxis.	82
5.4.	Maintenance therapy	84
5.4.1.	Standard maintenance	84
5.4.1.1.	Current practice	84
5.4.1.2.	Drugs for maintenance therapy	84
5.4.2.	Role of intensification of maintenance	85
5.4.3.	Maintenance therapy after autologous hematopoietic stem cell transplantation (autoHSCT)	86
5.4.4.	MRD-evaluation for decision making.	86
5.5.	The management of extramedullary ALL	88
5.5.1.	Incidence and site of extramedullary disease	88
5.5.2.	Prognostic factors	88
5.5.3.	Treatment strategies	88
5.5.3.1.	CNS disease	88
5.5.3.2.	Non-CNS extramedullary disease.	90
5.5.4.	Relapsed extramedullary disease	90
5.5.5.	Role of transplant	91
5.6.	Minimal residual disease	93
5.6.1.	Methods for MRD evaluation	93
5.6.2.	Standards and definitions	94
5.6.3.	Prognostic relevance of MRD	95
5.6.4.	MRD before and after Stem Cell Transplantation.	96
5.6.5.	Clinical application	97
5.6.6.	European Consensus Project.	98
5.7.	Stem cell transplantation	101
5.7.1.	Considerations for analysis of SCT results	101
5.7.2.	Results of SCT	102
5.7.3.	Comparisons of chemotherapy and SCT	104
5.7.4.	Conditioning.	104
5.7.5.	Post-transplant monitoring and treatment	107
5.7.6.	Prognostic factors for outcome of SCT	107
5.7.7.	Indications for SCT	112
5.8.	Philadelphia chromosome positive ALL (Ph+ ALL)	116
5.8.1.	Clinical characteristics	116
5.8.2.	Diagnosis	117
5.8.3.	Treatment of Ph/BCR-ABL+ ALL: Imatinib and chemotherapy	117

5.8.4.	CNS prophylaxis	120
5.8.5.	Allogeneic stem cell transplantation (SCT) after imatinib-based therapy	120
5.8.6.	Imatinib administration following SCT	121
5.8.7.	Mechanisms of resistance to therapy and progression	121
5.8.8.	Assessment of MRD	122
5.8.9.	Treatment of relapse	123
5.8.10.	Future treatment concepts	125
5.8.11.	Conclusions	126
5.9.	Burkitt lymphoma and leukemia	129
5.9.1.	Patients without HIV infection	129
5.9.1.1.	Diagnosis	129
5.9.1.2.	Treatment concepts and results	133
5.9.1.3.	Specific issues in supportive care	137
5.9.2.	B-ALL/Burkitt's NHL in patients with HIV infection	140
5.9.2.1.	Comparison of clinical-biologic characteristics with those from non HIV-infected patients	140
5.9.2.2.	Therapeutic approach	140
5.10.	Lymphoblastic lymphoma	142
5.10.1.	Immunophenotype	142
5.10.2.	Clinical features	142
5.10.3.	Therapy	143
5.10.4.	CNS prophylaxis	144
5.10.5.	Management of mediastinal tumors	144
5.10.6.	Prognostic factors	146
5.10.7.	MRD in T-LBL	146
5.10.8.	Stem cell transplantation in T-LBL	146
5.10.9.	Treatment of relapse	148
5.11.	ALL in adolescents and young adults	149
5.11.1.	Clinical and biologic characteristics in adolescents and young adults	149
5.11.2.	Pediatric-based vs adult-based treatments	150
5.11.3.	Role of hematopoietic stem cell transplantation in ALL in adolescents and young adults	153
5.12.	Elderly ALL	156
5.12.1.	Age-related clinical and biological differences	156
5.12.2.	Management of non-frail patients	157
5.12.3.	Management of frail patients	162
5.13.	ALL diagnosed in pregnant women	163
5.13.1.	Incidence	163
5.13.2.	Treatment approach and complications	164
5.13.3.	Ph+ ALL	164
5.13.4.	Supportive therapy	164
5.13.5.	Timing of delivery	165
5.13.6.	Fetal outcome and breastfeeding	165
5.14.	ALL in Jehovah's Witness	166
6.	Management of Ph- ALL Relapse / New Drugs in Ph- ALL	172
6.1.	Outcome of adult patients with Ph- ALL in first relapse	172
6.2.	Salvage chemotherapy studies	173
6.3.	Post-transplant relapses	175

6.4.	New drugs in Ph- ALL.....	175
6.4.1.	New nucleoside analogs.....	175
6.4.2.	New formulations of existing agents.....	176
6.4.3.	Monoclonal antibodies.....	177
6.4.4.	New antimetabolites.....	178
6.4.5.	Targeted molecular therapies.....	178
6.5.	Conclusion.....	178
7.	Late Effects of Therapy	184
7.1.	Definitions.....	184
7.2.	Type of late effects in cured ALL patients.....	184
7.3.	Late effects after stem cell transplantation.....	187
7.4.	Late effect assessment in the GMALL studies.....	187
7.5.	Quality of life in ALL patients.....	187
7.6.	Patient advice and after-care.....	188
7.7.	Summary.....	188
8.	EWALL Consensus Definitions	194
9.	European Study Groups for Adult ALL	204